PULM Pulmatrix Corporation Total Debt to Capital
The immediate trigger for Pulmatrix, Inc. (PULM) will be the disclosure of trial results for powder-based agents against pulmonary fungi, while the market capitalization already prices in past failures and liquidity shortages. The company focuses on inhalation therapy, relying on grants and clinical trial success due to a lack of recurring revenue. This price chart on GURU.Markets illustrating trading dynamics shows a debt-to-equity ratio of 0.00, confirming its status as a reputable developer of drug delivery systems.
Analytical breakdowns and data insights for company Pulmatrix Corporation (PULM)
The high scalability of Pulmatrix, Inc. (PULM) inhalation technologies requires significant funding for global market expansion. The historical trend of the total debt-to-equity ratio reflects the proportion of borrowed funds to net assets, allowing for an assessment of the financial leverage level and the impact of the weighted average cost of capital (WACC) on the overall balance sheet stability of Pulmatrix, Inc. (PULM) during periods of cyclical sector development.